Advanced Filters
noise
Found 1,274 clinical trials
R Reception Outpatient Clinic

IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition

This is a monocentric, randomized pilot study conducted at the Max Planck Institute of Psychiatry, Munich. The study investigates the effects of two different intermittent theta-burst stimulation (iTBS) schedules on biological and clinical outcomes in patients with depression and comorbid Post-COVID-19 condition (PCC). Participants will be randomized into two arms, …

18 - 65 years of age All Phase N/A
L Lauren Enten, B.S.A.

Psilocybin rTMS for Treatment Resistant Depression

The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

22 - 65 years of age All Phase 2
A Afifa Humaira

Left vs. Right Non-Inferiority Trial

The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).

18 - 65 years of age All Phase N/A
J Julie Farrington, MD

Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

This is a single-site open-label clinical trial of the Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) protocol. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS) and specifically as SAINT®-is effective as a first-line …

14 - 19 years of age All Phase N/A

Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)

This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minutes daily (Monday through Friday) over …

24 - 65 years of age All Phase N/A
J Jyoti Mishra, PhD

Mindfulness Engaged Neurostimulation for Depression

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of ~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may …

18 - 60 years of age All Phase 2
N Nili Solomonov, PhD

Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

The investigators hypothesized that during the 9-week course of Engage & Connect treatment there will be an increase in brain functions of the Positive Valence System which in turn will lead to reduction in suicidality.

50 - 80 years of age All Phase N/A
N Natalia Jaworska, PhD

Effects of Aerobic Exercise Intensity on Clinical & Neural Outcomes in Depressed Youth

This study will assess the effects of moderate vs. high intensity aerobic exercise, performed 3 times a week for 12 weeks under supervised conditions, on symptoms of depression, cognitive functioning and brain function in transitional aged youth (TAY: aged 16-24 years).

16 - 24 years of age All Phase N/A
W Wang Huaning

Effect of Individualized Precise TMS on Emotional Blunting in Depression and Its Brain Imaging Mechanism

This study aims to explore and investigate the therapeutic effect and mechanism of individualized localization of transcranial magnetic stimulation on emotional blunting of depression, improve the understanding of the mechanism of emotional blunting of depression, order to provide new treatment methods and better curative effects for this disease.

18 - 65 years of age All Phase N/A

WiserAD: The Effect of a Structured Online Intervention on Antidepressant Deprescribing in Primary Care

The use of antidepressants (ADs) is increasing globally, including within Australia, which has one of the highest rates of AD prescribing. Despite clear benefits for many people, there is reason to believe that the ongoing use of these medications is often not properly monitored or stopped (deprescribed) when a person …

18 - 75 years of age All Phase N/A

Simplify language using AI